MML Investors Services LLC Purchases 19,113 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

MML Investors Services LLC boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 103.6% in the third quarter, HoldingsChannel reports. The institutional investor owned 37,566 shares of the medical equipment provider’s stock after purchasing an additional 19,113 shares during the quarter. MML Investors Services LLC’s holdings in Zimmer Biomet were worth $4,055,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ZBH. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Bangor Savings Bank purchased a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $31,000. Family Firm Inc. bought a new stake in shares of Zimmer Biomet during the second quarter valued at approximately $33,000. Finally, Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the third quarter worth $35,000. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZBH. Raymond James cut their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. BTIG Research cut their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research report on Thursday, October 3rd. Royal Bank of Canada boosted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Wolfe Research initiated coverage on Zimmer Biomet in a report on Tuesday, September 10th. They set a “peer perform” rating for the company. Finally, Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $122.83.

Zimmer Biomet Stock Down 0.1 %

Shares of NYSE:ZBH opened at $106.74 on Friday. The firm has a market capitalization of $21.25 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The business has a 50 day simple moving average of $107.69 and a two-hundred day simple moving average of $108.75. Zimmer Biomet Holdings, Inc. has a 1 year low of $101.47 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the previous year, the business earned $1.65 EPS. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.